ArticleCancer2022

Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.

Julie R Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.